Literature DB >> 24346004

Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC.

Sarah Payton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24346004     DOI： 10.1038/nrurol.2013.308

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

2.  Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Authors:  Brian I Rini; Joaquim Bellmunt; Jill Clancy; Kongming Wang; Andreas G Niethammer; Subramanian Hariharan; Bernard Escudier
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544
  2 in total
  1 in total

1.  Immune-related long non-coding RNAs can serve as prognostic biomarkers for clear cell renal cell carcinoma.

Authors:  Cheng Shan Li; Zhang Ze Lu; Da Lang Fang; Wei Jie Zhou; Jie Wei
Journal:  Transl Androl Urol       Date:  2021-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.